Difference between revisions of "Depression in Parkinson's disease"
(Created page with "'''Diagnosis''' * be aware of significant overlap between depressive symptoms with PD, including psychomotor slowing, lack of facial expression, fatigue, and diminished atten...") |
|||
| Line 1: | Line 1: | ||
'''Diagnosis''' | '''Diagnosis''' | ||
| − | * | + | * Be aware of significant overlap between depressive symptoms with PD, including psychomotor slowing, lack of facial expression, fatigue, and diminished attention (Timmer et al, 2017) |
| − | * | + | * Distinguish depression (high degree of subjective suffering) from apathy (low degree of subjective suffering) (Timmer et al, 2017) |
| − | * | + | * Distinguish psychotic features from depression (mood congruent) from psychotic features 2/2 dopaminergic treatment or cognitive decline (mood incongruent) (Timmer et al, 2017) |
* PD patients with depression seem more vulnerable to developing impulse control disorders 103 (see below) | * PD patients with depression seem more vulnerable to developing impulse control disorders 103 (see below) | ||
| Line 9: | Line 9: | ||
'''Treatment''' | '''Treatment''' | ||
| − | * | + | * Is depression related to motor fluctuations or undertreatment? |
** In a study examining nonmotor symptoms related to on and off periods, patients presented higher depression and anxiety scores in the wearing-off periods, as well as worse semantic verbal fluency and executive function performance (Caillava-Santos, Margis, and Rieder, 2015) | ** In a study examining nonmotor symptoms related to on and off periods, patients presented higher depression and anxiety scores in the wearing-off periods, as well as worse semantic verbal fluency and executive function performance (Caillava-Santos, Margis, and Rieder, 2015) | ||
** Optimize dopaminergic regimen; levodopa may have an antidepressant effect; other dopamine receptor agonists have shown antidepressant effect, such as pramipexole, which was statistically greater than placebo (Barone et al, 2010) and similar to sertraline antidepressant effect (Barone et al, 2006) | ** Optimize dopaminergic regimen; levodopa may have an antidepressant effect; other dopamine receptor agonists have shown antidepressant effect, such as pramipexole, which was statistically greater than placebo (Barone et al, 2010) and similar to sertraline antidepressant effect (Barone et al, 2006) | ||
Revision as of 11:35, 12 June 2021
Diagnosis
- Be aware of significant overlap between depressive symptoms with PD, including psychomotor slowing, lack of facial expression, fatigue, and diminished attention (Timmer et al, 2017)
- Distinguish depression (high degree of subjective suffering) from apathy (low degree of subjective suffering) (Timmer et al, 2017)
- Distinguish psychotic features from depression (mood congruent) from psychotic features 2/2 dopaminergic treatment or cognitive decline (mood incongruent) (Timmer et al, 2017)
- PD patients with depression seem more vulnerable to developing impulse control disorders 103 (see below)
Treatment
- Is depression related to motor fluctuations or undertreatment?
- In a study examining nonmotor symptoms related to on and off periods, patients presented higher depression and anxiety scores in the wearing-off periods, as well as worse semantic verbal fluency and executive function performance (Caillava-Santos, Margis, and Rieder, 2015)
- Optimize dopaminergic regimen; levodopa may have an antidepressant effect; other dopamine receptor agonists have shown antidepressant effect, such as pramipexole, which was statistically greater than placebo (Barone et al, 2010) and similar to sertraline antidepressant effect (Barone et al, 2006)
References
Barone, P. et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: A national multicenter parallel–group randomized study. J. Neurol. 253, 601–607 (2006). https://pubmed.ncbi.nlm.nih.gov/16607468/
Barone, P. et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 573–580 (2010). https://pubmed.ncbi.nlm.nih.gov/20452823/
Caillava-Santos, F., Margis, R. & Rieder, C. Wearing-off in Parkinson’s disease: neuropsychological differences between on and off periods. Neuropsychiatr. Dis. Treat. 1175 (2015) doi:10.2147/NDT.S77060. https://pubmed.ncbi.nlm.nih.gov/25999721/
Timmer, M. H. M., van Beek, M. H. C. T., Bloem, B. R. & Esselink, R. A. J. What a neurologist should know about depression in Parkinson’s disease. Pract. Neurol. 17, 359–368 (2017). https://pubmed.ncbi.nlm.nih.gov/28739866/
